Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Next Previous
Search
Trial Profile

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linsitinib (Primary)
  • Indications Graves ophthalmopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms LIDS
  • Sponsors Sling Therapeutics

    • Most Recent Events

    • 14 Jan 2025 According to Sling Therapeutics Media Release, Primary endpoint (Percentage of Subjects who are Proptosis Responders at Week 24) has been met.
    • 14 Jan 2025 Results presented in the Sling Therapeutics Media Release
    • 13 Jan 2025 According to a Sling Therapeutics media release, topline data from this trial, presented at the 43rd Annual J.P. Morgan Healthcare Conference being held January 13-16, 2025, in San Francisco,CA. Raymond Douglas Chief Scientific Officer of Sling Therapeutics presented the results of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top